Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SLC5A7 | Q9GZV3 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18884429 | 0.78 | EPHX2 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL12852537 | 0.76 | EPHX2 (0.49) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL15470638 | 0.76 | EPHX2 (0.56) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL10864502 | 0.73 | EPHX2 (0.44) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL6404881 | 0.73 | SLC5A7 (0.59) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL3862171 | 0.73 | EPHX2 (0.53) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL442507 | 0.72 | NOTUM (0.43) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL2306096 | 0.72 | LMNA (0.45) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL6403886 | 0.72 | SLC5A7 (0.53) | EPHX2RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL6408017 | 0.71 | SMN1; SMN2 (0.53) | EPHX2RAB9ANPC1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | EPHX2 811/4885RAB9A 3193/4885NPC1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.